Achieve Life Sciences (ACHV) vs Attovia Therapeutics (ATTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($749.6 million vs $746.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | ATTO |
|---|---|---|
| Share price | $7.24 | $16.42 |
| Market cap | $746.46M | $749.59M |
| 1-day change | +2.99% | -6.17% |
| YTD return | +45.67% | — |
| 1-year return | +118.07% | — |
| 5-year return | -10.06% | — |
| EPS (TTM) | $-1.69 | $-2.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $28.00 |
| 52-week low | $2.62 | $16.15 |
| Distance from 52-week high | -16.20% | -41.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +95.44% | +157.00% |
| Average volume | 1.44M | 458.24K |
| Shares outstanding | 103.10M | 45.65M |
| Employees | 28 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
ACHV vs ATTO FAQ
Which is bigger, Achieve Life Sciences or Attovia Therapeutics?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $749.59M compared with $746.46M for Achieve Life Sciences (ACHV).
Are Achieve Life Sciences and Attovia Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Achieve Life Sciences and Biotechnology: Biological Products (No Diagnostic Substances) for Attovia Therapeutics.